Stent implantation in the popliteal artery is feasible.

Original title: Treatment of Complex Atherosclerotic PoplitealArtery Disease With a New Self-Expanding Interwoven Nitinol Stent. 12-Month Results of the Leipzig SUPERA Popliteal Artery Stent Registry. Reference: Dierk Scheinert, et al. J Am Coll Cardiol Intv 2013;6:65–71

Currently, peripheral angioplasty (PTA) of the popliteal artery is a real challenge since stent implantation is controversial and the outcome of balloon angioplasty does not always present better results. The aim of this registry was to evaluate the efficacy of the SUPERA nitinol stent at one year, (IDEV Technologies, Webster, Texas), in complex popliteal obstructions.

101 patients were included between January 2008 and April 2010. They all received the SUPERA stent in the popliteal artery, this being the only inclusion criterion.

All were symptomatic with an ankle-brachial index of 0.58 ± 0.15. Half had moderate or severe calcification and stents were implanted in a total of 125. Primary permeability at 12 months was 87.7 ± 3% and the secondary was 96.5 ± 2% with a significant improvement in claudication. The ankle- brachial index also improved from 0.58 ± 0.15 at baseline to 0.97 ± 0.18 after one year (p <0.001). During follow-up a total of 10 patients died, 9 of which were from cardiovascular causes unrelated to the procedure. An acute occlusion was present in one patient and required amputation of the treated limb but he died two months later. This last patient was the only death related to the procedure as well as the only amputation. Radiological control was observed in 51 patients without stent fracture. 

Conclusion: 

At 12 months follow up, both the permeability and durability of the SUPERA stent over popliteal level were high.

Comment: 

The results encourage us to use stents in this territory but we must be aware that not all devices are equal. More studies are still needed to show the safety and efficacy of stents in the popliteal artery, while the use of a stent should be temporary to a suboptimal balloon result. 

Courtesy by Dr Carlos Fava.
Interventional Cardiologist
Favaloro Foundation. Argentina.

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....